<p>This is a summary of the European public assessment report (EPAR) for Reagila. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Reagila.</p><p>For practical information about using Reagila, patients should read the package leaflet or contact their doctor or pharmacist.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Reagila is indicated for the treatment of schizophrenia in adult patients.</p></div>
Therapeutic Area (MeSH)
ATC Code
N05AX15
ATC Item
N/A
Pharmacotherapeutic Group
Psycholeptics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| cariprazine hydrochloride | N/A | cariprazine hydrochloride |
EMA Name
Reagila
Medicine Name
Reagila
Aliases
N/ANo risk management plan link.
